Louise Winteringham leads the Translational Cancer Research Program at the Perkins. Shas an extensive background in immunology and haematology focusing on the molecular and cellular biology of cancer, in particular haematological cancers. She completed her MSc in the Department of Clinical Immunology at Royal Perth Hospital investigating the impact of non-coding regions within the Major Histocompatibility Complex. Following three years working at St Bartholomew's Hospital in London, Louise was awarded the Richard Walter Gibbon Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at UWA to undertake her PhD so she returned to Perth where she joined the Leukemia Laboratory at WAIMR, headed by Professor Peter Klinken. Louise continued her work in cancer research focusing on the biochemical and cellular mechanisms that drive oncogenesis. She has identified several novel genes associated with the development and progression of cancer. In 2017 she initiated the Translational Cancer Research Program at The Perkins, developing collaborations with pathologists and surgeons to provide a co-ordinated approach to quickly move laboratory discoveries into cancer treatments. As part of this program, she has established pre-clinical models able to accurately evaluate new cancer treatments that modulate our own immune systems to fight cancer. These models are currently being used to develop precision oncology medicine in combination with several omics technologies.